When was Crux Biolabs founded?

Crux Biolabs was founded in 2011.

Where is Crux Biolabs located?

Crux Biolabs is headquartered in Bayswater, Australia.

Who is the current CEO of Crux Biolabs?

Catherine Osborne of Crux Biolabs.

How many employees does Crux Biolabs have?

As of Aug 31, 2026, the latest employee count at Crux Biolabs is 61.

Where does Crux Biolabs rank among its competitors?

Crux Biolabs ranks 70th amongst 114 active competitors, of which 30 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Cellply, which secured $8.36M in May, 2026.

Who are the top competitors of Crux Biolabs?

Crux Biolabs' top competitors include Bit.bio, Cellply and Kiyatec. Among them, Cellply secured the most recent funding round in May, 2026.

Crux Biolabs - 2026 Company Profile, Team, Funding & Competitors

Crux Biolabs is an acquired company based in Bayswater (Australia), founded in 2011. It operates as a Provider of biomarker detection & cell-based assays for drug development. The company has 114 active competitors, including 30 funded and 15 that have exited. Its top competitors include companies like Bit.bio, Cellply and Kiyatec.

Company Details

Provider of biomarker detection & cell-based assays for drug development. The company specializes in immunology services and cell assays for a wide range of studies including vaccines, Immunotherapies, Immuno-Oncology, and Infectious diseases.

Website: cruxbiolabs.com
Email ID: *****@cruxbiolabs.com
Phone Number: +61 **********

Key Metrics

Founded Year

2011

Location

Bayswater, Australia

Stage

Acquired

Investors

Leading Technology Group

Ranked

70^th among 114 active competitors

Employee Count

61 as on Aug 31, 2026

Similar Companies

Bit.bio & 153 more

Exit Details

Acquired by Genesis Capital (Aug 04, 2022)

View Crux Biolabs' full profile

Crux Biolabs got acquired by Genesis Capital on Aug 04, 2022.

Click here to take a look at Crux Biolabs's acquisition in detail

Crux Biolabs is a funded company. Crux Biolabs has 1 institutional investor.

View details of Crux Biolabs's funding rounds and investors

Crux Biolabs' employee count trend

Crux Biolabs has 61 employees as of Aug 26. Here is Crux Biolabs's employee count trend over the years:

Uncover Crux Biolabs' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Crux Biolabs include Bit.bio, Cellply and Kiyatec. Here is the list of Top 10 competitors of Crux Biolabs, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Bit.bio 2016, Cambridge (United Kingdom), Series C	Manufacturer of programmed human cells for research and drug discovery	$266M	M&G, Foresite Capital & 53 others	67/100
2nd	Cellply 2013, Bologna (Italy), Series B	Developer of in-vitro diagnostic products for the detection of cancer	$16.4M	LIFTT, Indaco Venture Partners & 15 others	60/100
3rd	Kiyatec 2005, Pendleton (United States), Series C	Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment	$29.5M	VentureSouth, MBD Biotech & 13 others	55/100
4th	CytoTronics 2015, Boston (United States), Series A	Developer of cell-based assays for drug discovery	$22.8M	Anzu Partners, BoxOne Ventures & 1 others	55/100
5th	Saguaro 2020, Quebec City (Canada), Seed	Developer of 3D cell culture products for drug discovery	$4.1M	Anges Quebec, AQC Capital & 3 others	50/100
6th	Pelago Bioscience 2013, Solna (Sweden), Seed	Assay services for use in the determination and quantification of drug-target interactions	-	Impilo, Europa & 1 others	48/100
7th	Cytotheryx 2018, Rochester (United States), Series A	Developer of human hepatocytes for research and clinical applications	$60M	Ouroboros Family Founders Fund I, QRS Investments ... & 1 others	47/100
8th	StemBioSys 2010, San Antonio (United States), Series A	Cell culture technology company advancing regenerative medicine and drug discovery	$14.5M	JLABS, Targeted Technology & 3 others	45/100
9th	SK Plasma 1970, Seongnam-si (South Korea), Funding Raised	Manufactures plasma derivatives	-	Korea Investment Holdings	45/100
10th	Nanocrine 2018, Frederick (United States), Seed	Provider of a cell analysis and drug design tool for researchers	$300K	TEDCO, America’s Seed Fund	43/100
70th	Crux Biolabs 2011, Bayswater (Australia), Acquired	Provider of biomarker detection & cell-based assays for drug development	-	Leading Technology Group	25/100